Does TRT Cause Prostate Cancer? What 80 Years of Research Actually Shows

The fear of testosterone and prostate cancer traces back to a single experiment published in 1941, and understanding why that experiment led medicine in the wrong direction for over eighty years requires understanding what the experiment actually showed.

Charles Huggins was studying men with advanced, metastatic prostate cancer, meaning cancer that had already spread beyond the prostate. He noticed that when these men were castrated, removing the primary source of testosterone from their bodies, their cancer markers dropped. So he did the reverse: he took castrated men with active metastatic prostate cancer and injected them with testosterone, and the cancer markers came back up. Huggins won the Nobel Prize for this work, and the medical community drew what seemed like an obvious conclusion. If removing testosterone slows the cancer, then adding testosterone must feed it.

That conclusion was logical. It just wasn't complete.

What the 1941 experiment actually demonstrated was that castrated men with active metastatic cancer responded to testosterone injections. It said nothing about whether normal testosterone levels cause prostate cancer in healthy men, and it said nothing about what happens when you raise testosterone from low to normal rather than from zero to supraphysiologic. But for decades, nobody questioned the leap.

The piece that was missing is something called the saturation model, which is the idea that prostate tissue can only use so much testosterone before it hits a ceiling and stops responding. The androgen receptors inside prostate cells are like parking spots in a lot. Once every spot is filled, more cars arriving outside the lot don't change anything inside it. Research published in 2009 identified that saturation point at roughly 240 to 250 nanograms per deciliter of testosterone, which is a level that most men, even men with low testosterone, already exceed.

This matters enormously because TRT is not taking someone from 250 to 2,500. TRT is taking someone from somewhere around 200 to 400 up into the range of 500 to 700, which is normal physiological territory and well above the saturation threshold the entire time. Below 250, changes in testosterone have a real and measurable effect on the prostate. Above 250, the prostate has essentially stopped listening.

So the relevant question was never whether extremely high testosterone affects prostate cancer in castrated men who already have it. The relevant question was whether raising testosterone from low-normal to normal in healthy men increases their risk of developing prostate cancer. And when researchers finally ran that study at scale, the answer was no.

The largest trial on this question followed 5,204 men over roughly 33 months and compared testosterone replacement therapy directly against placebo. Prostate cancer developed in 0.46 percent of the TRT group and 0.42 percent of the placebo group, a hazard ratio of 1.07 with a p-value of 0.87, which is about as close to no difference as data gets. A separate population study out of Finland followed 78,615 men for 18 years and found that prostate cancer-specific mortality was actually lower in TRT users, with a hazard ratio of 0.52, meaning TRT users were roughly half as likely to die of prostate cancer over that period. A 2024 meta-analysis pooling 28 randomized controlled trials found that PSA, which is a blood marker for prostate activity, changed by an average of 0.08 nanograms per milliliter in men on TRT, a number so small it is considered clinically meaningless.

The most important data point, though, is the one that closes the argument.

Researchers looked at 69,984 men who had already been treated for localized prostate cancer, and of those, 1,012 received testosterone therapy afterward. If testosterone fed prostate cancer, these would be the men most at risk. Their existing cancer, even in remission, would be the most vulnerable to any testosterone-driven recurrence. There was no increase in recurrence. There was no increase in death. If testosterone does not accelerate existing prostate cancer in men who have already had it, the mechanism by which it would cause prostate cancer from scratch in healthy men becomes very hard to construct.

What this means practically is that TRT does not require you to choose between hormone health and prostate safety. It does require reasonable monitoring, because some men do have undetected prostate cancer at the time they begin TRT, and rising PSA can be an early signal. The Endocrine Society's clinical practice guidelines recommend getting a baseline PSA before starting, rechecking at three to six months, and then annually after that. If PSA rises more than 1.4 nanograms per milliliter above your personal baseline, that warrants a conversation with a urologist, not because TRT caused anything, but because that signal deserves investigation regardless of its cause.

The 1941 experiment was not wrong. Testosterone does affect prostate cancer in men who have been castrated and already have active metastatic disease. That finding is real and it still informs how advanced prostate cancer is treated today. What was wrong was the extrapolation, the assumption that a finding in a very specific population under very specific conditions applied universally to all men considering testosterone therapy.

Eighty years of accumulated data in tens of thousands of men could not find the harm that one experiment seemed to promise. At some point, the absence of evidence becomes evidence of absence, and we are well past that point here.

---

References

1. Huggins CV, Hodges CV. 1941. "Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate." Cancer Research. 14:293-297. Finding: Castration reduced acid phosphatase in men with metastatic prostate cancer; testosterone injection into castrated men raised it back. Source
2. Morgentaler A, Traish AM. 2009. "Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth." European Urology. 552:310-320. Finding: Prostate androgen receptors saturate at approximately 240-250 ng/dL; above this threshold, additional testosterone produces minimal prostate effect. Source
3. Bhasin S, Travison TG, Pencina KM, et al. 2023. "Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial." JAMA Network Open. 612:e2348692. Finding: 5,204 men, 33 months. Prostate cancer: 0.46% TRT vs 0.42% placebo HR 1.07, p=0.87. No significant difference. Source
4. Siltari A, Murtola TJ, Kausz J, et al. 2023. "Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men." Acta Oncologica. 6211-12:1755-1762. Finding: 78,615 men, 18-year follow-up. Prostate cancer-specific mortality LOWER in TRT users HR 0.52. Source
5. Xu Z, Chen X, Zhou H, et al. 2024. "An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate." Frontiers in Endocrinology. 15:1335146. Finding: 28 RCTs. PSA change: 0.08 ng/mL not significant. IPSS change: 0.00 literally zero difference. Source
6. Sarkar RR, Patel SH, Parsons JK, et al. 2021. "Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease." Prostate Cancer and Prostatic Diseases. 24:739-746. Finding: 69,984 men with treated prostate cancer, 1,012 received TRT. No increase in recurrence or death. Source
7. Bhasin S, Brito JP, Cunningham GR, et al. 2018. "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline." JCEM. 1035:1715-1744. Finding: Refer to urology if PSA rises >1.4 ng/mL above baseline. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness